The European market for neuroleptic drug therapies is forecast to grow from a value of $646.9 million in 1994 to $921 million by the year 2000, says a new study from Frost & Sullivan.
The market numbers about 35 products. F&S says the most dynamic and interesting segment, atypical neuroleptic drugs, is now worth $74.4 million and should reach $170 million by 2000. One atypical product, Janssen's new dopamine/serotonin antagonist Risperdal (risperidone), is expected to penetrate the whole European market by 2000. Other atypical products, such as seroquel, sertindole, olanzapine and zotepine, are forecast to prove major treatments in the second half of the 1990s.
The classic neuroleptic market is forecast to grow from $582.4 million in 1994 to $743.4 million by 2000, says F&S.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze